Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 158.5× sales vs its 27.0× historical median P/S.
Fair value ≈ $15.31 · price $90.00 today
Overvalued · 488% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CMPX here is a data point for the large unmet need in btc. fda just approved $MRUS bizengri for 2l nrg1+ btc based on data from 19 patients in a single arm open label trial. approval was granted in less than a month after sBLA submission! https://www.curetoday.com/view/fda-approves-bizengri-for-advanced-unresectable-or-metastatic-cholangiocarcinoma
$IBRX 10-year analyst consensus revenue estimates versus the like 10-year revenue forecast prepared by $MRUS management/BOD & provided $GMAB.
Analysts forecast IBRX to generate considerably more revenues than MRUS for the next 5 years & 8% more over the next 10 years as a whole.
GMAB acquired IBRX for an enterprise value of roughly $7.3B. IBRX's market cap = $5.8B & a $6.4B enterprise value (includes a royalty financing).
IBRX gross margins have been 99% (technically rounded to 100%). MRUS did not provide a gross margin forecast in their 14D9 filing.
This is for entertainment purposes only. This is not investment advice.
$XBI $IBB
$MRUS Conditions are shifting toward markets rewarding operational proof over narrative ambition. Competitive differentiation has to become evident in core KPIs. Missteps would reset expectations abruptly. Sentiment should follow consistency rather than noise.
$PYXS 5 discontinued patients are all over-weighted, dosing will be adjusted well based on body weight going forward.
Purely oversold and overreaction by market.
$MRUS $CRBP
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know).
Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025.
This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months.
If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared.
$XBI $IBB
$MRUS
Current Stock Price: $96.23
Contracts to trade: $95 MRUS Dec 19 2025 Call
Entry: $2.34
Exit: $3.98
ROI: 70%
Hold ~27 days
Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B.
NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B.
This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years.
$XBI $IBB
$MRUS advances immunotherapy development with a diversified pipeline. AERT reinforced its scalable GCC model, positioning for accelerated second-half growth.
